Odpovedal: Ivan pre všetkých
Re: Sirup proti kaslu a alkohol,rychlo prosim
(číslo príspevku 178.630, zo dňa 18.01.2009. videné 448x)
ODPOVEDAŤ / Predchádzajúci príspevok 		 

Text príspevku číslo 178630:
Nakoľko tu bolo o echinacei, tak som Vám vyhľadal dvojitý slepý pokus s preparátom obs. echinaceu. Je to v angličtine, ale v krátkosti preložím najdôležitejší záver.
Inak táto štúdia bola publikovaná v JAMA to je jeden z najznámejších odborných časopisov vo svete. Patrí k medicinskej špičke. Dokonca lekár ktorý má v tomto časopise článok môže byť na seba hrdý. Chcem upozorniť na 700 pacientov ktorý boli do štúdie zahrnutí. Všetko to boli deti a išlo o prechladnutie. Záver je taký ako som tu už písal. Nie je rozdiel oproti placebu a je zvýšené riziko vyrážok u pacientov v liečbe echinacou. Kto vie po anglicky, tak si ľahko prečíta a ľahko porozumie. A pre tých ktorí majú dobrú skúsenosť, to je fajn, ale medicínu nemôže zaujímať jeden, dvaja. Musí byť objektivita, musí to byť štatisticky významné a ak skúšam na sebe nejaký liek nemôžem vedieť či si v skutočnosti dávam liek alebo placebo. A až následne ak to vyhodnotím tak viem či to pomáha a čí nie. Chcem upozorniť, že vybral som štúdiu publikovanú v renomovanom časopise s veľkou skupinou pacientov. Mohol by som sem dať aj iné, ktoré dopadli podobne. Jednu dokonca dal Juraj. Mimochodom Juraj dal štúdiu pri liečbe otitíd, tj. zápalu uší. Každý kto má deti a tie mali zápal ušiek vie, že u detí je otitida najčastejšia komplikácia práve pri prechladnutí.

Dec. 3, 2003 — Echinacea was not found effective in treating upper respiratory tract infection (URI) symptoms in patients 2-11 years old, and was associated with an increased risk of rash, according to the results of a randomized, double-blind, placebo-controlled trial published in the Dec. 3 issue of The Journal of the American Medical Association.

The authors postulated that treatment with echinacea would reduce the duration and severity of URI symptoms in the pediatric population. Their four-month study included 407 patients aged two to 11 years, of whom 207 were randomized to the placebo group. Of the 200 patients in the echinacea treatment group, children aged two to five years received 7.5 mL/day (50% of manufacturer's adult recommended dose), while those aged six to 11 years were administered 10 mL/day (67% of recommended dose). Treatment began with symptom onset and continued until complete resolution at a maximum of 10 days.

A total of 759 URIs were confirmed in study patients, 337 of which occurred in the echinacea group and 370 in the placebo cohort. This difference is largely due to fewer second and third URIs among children randomized to the echinacea group compared with the placebo group (52.3% vs. 64.4%; P = .015).

There were no statistically significant differences in outcome between echinacea and placebo treatment groups in terms of duration of symptoms (median, 9 days; 95% confidence interval [CI], 8 - 10 days; P = .89), or severity of symptoms (median Likert severity scale summation for both groups, 33; 95% CI, 29 - 40 days for the echinacea group vs. 30 - 38 days for the placebo group; P = .69). In addition, there were no significant differences in peak severity of symptoms (P = .69), number of days of peak symptoms (mean, 1.60 vs. 1.64 days; P = .97), number of days of fever (mean, 0.81 vs. 0.64 days; P = .09), or parental global assessment of the severity of the cold (P = .67). Although adverse events were reported in 42.5% of study URIs with no significant difference between the two treatment groups (P = .14), rashes were more frequent in the echinacea group compared with the placebo group (7.1% vs. 2.7%; P = .008).

"Given its lack of documented efficacy and an increased risk for the development of rash, our results do not support the use of echinacea for treatment of URIs in children 2 to 11 years old. Further studies using different echinacea formulations, doses and dosing frequencies are needed to delineate any possible role for this herb in treating colds in young patients," the authors conclude.

This project was supported by the National Center for Complementary and Alternative Medicine. Study medication and placebo were provided by Madaus AG, Cologne, Germany. The formulation of echinacea used in the study (EC31J2) is marketed as Echinacin Saft.

JAMA. 2003;290:2824-2830